Evidence map›Paper›PMID 39641480›Full record

ReviewTherapeutic delivery2025

Topical dutasteride for androgenic alopecia: current state and prospects.

Jayanaraian F M Andrade, Andrew Verbinnen, Andrew Bakst, Marcílio Cunha-Filho, Guilherme M Gelfuso, Taís Gratieri

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Translational andrology and urology · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jayanaraian F M AndradeLaboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia (UnB), Brasília, Brazil.
Andrew VerbinnenHairDAO Association, County of Sussex, DE, USA.
Andrew BakstHairDAO Association, County of Sussex, DE, USA.
Marcílio Cunha-FilhoLaboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia (UnB), Brasília, Brazil.
Guilherme M GelfusoLaboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia (UnB), Brasília, Brazil.
Taís GratieriLaboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia (UnB), Brasília, Brazil.ORCID 0000-0001-6481-2364

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgenic alopecia has a high incidence, affecting 80% of men and 50% of women in their lifetimes. Although not a life-threatening disease, it can be a deep psychological burden to patients and still lacks an effective and safe treatment. Dutasteride is a5-alpha-reductase inhibitor approved to treat benign prostatic hyperplasia that is also commonly prescribed

Indexed as

5-alpha Reductase InhibitorsAlopeciaDutasterideAdministration, TopicalAnimalsCosmeticsDrug CarriersFemaleFinasterideHair FollicleHumansMaleMinoxidilNanoparticles5-alpha Reductase InhibitorsCosmeticsDrug CarriersDutasterideFinasterideMinoxidilHair folliclesnanocarriersnanotechnologyskintopical delivery

Identifiers

PMID39641480
PMCPMC11875473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.